San Diego-Shanghai biotechnology startup RuiYi Inc has entered into an exclusive license and collaborative development agreement with Shanghai-based Genor BioPharma to develop the RYI-008 molecule in China.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
RuiYi, Genor, RYI-008, cancer